Myeloproliferative disorders drugs market to be worth $9.26 billion by 2023

The global market for drugs to treat myeloproliferative disorders is expected to be valued at $9.26 billion by 2023, expanding at a compound annual growth rate (CAGR) of 3.4% during the forecast period.

According to a new report from Grand View Research, myeloproliferative disorders due to changing lifestyles, growing geriatric population, and increasing public awareness are some of the primary growth stimulants for the market. Therapeutic development in second-line setting for Jakafi-intolerant patients is estimated to work in favor of the Ph- MPNs market.

Chronic myeloproliferative disorders are rare hematological malignances that involve abnormal accumulation of mature myeloid cells (red blood cells, granulocytes, and platelets) and their precursors (myelocytes, metamyelocytes, nucleated red blood cells, and megakaryocytes) in the peripheral blood and bone marrow. This class of disorder includes four main myeloproliferative diseases, which are further categorized by the presence of the Philadelphia chromosome.